Investor Relations

We seek to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with our shareholders.

Symbol

NASDAQ : ASBP

Price

^$

Volume

Change

Delayed up to 15 minutes

Latest News

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS...

All News

Latest Presentation

Presentations

Stock Information

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Detailed Stock Information

Email Alerts

Subscribe to Aspire’s Investor Relations Email Alerts to receive direct real-time updates on market data, financial reports, and SEC filings.

Subscribe

IR Contacts

Corporate Office

Aspire Biolabs
23150 Fashion Drive,
Suite 232,
Estero, FL 33928
United States

Investor Relations

TraDigital IR
Kevin McGrath
Managing Director
575 Fifth Avenue, 14th Fl
NY, NY 10017
(646) 418-7002
[email protected]

Transfer Agent

Colonial Stock Transfer Co, Inc.
7840 S. 700 E.
Sandy, UT 84070
(801) 355-5740